S&P 500   3,916.64
DOW   31,861.98
QQQ   305.05
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Fed's Shocking New Plan to Control Your Money (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Niinistö: Sweden security OK if Finland joins NATO first
Fed's Shocking New Plan to Control Your Money (Ad)
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.05
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Fed's Shocking New Plan to Control Your Money (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Niinistö: Sweden security OK if Finland joins NATO first
Fed's Shocking New Plan to Control Your Money (Ad)
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.05
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Fed's Shocking New Plan to Control Your Money (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Niinistö: Sweden security OK if Finland joins NATO first
Fed's Shocking New Plan to Control Your Money (Ad)
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.05
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Fed's Shocking New Plan to Control Your Money (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Niinistö: Sweden security OK if Finland joins NATO first
Fed's Shocking New Plan to Control Your Money (Ad)
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ABIO

ARCA biopharma - ABIO Stock Forecast, Price & News

$2.14
+0.01 (+0.47%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$2.05
$2.14
50-Day Range
$2.02
$2.49
52-Week Range
$1.76
$2.70
Volume
60,700 shs
Average Volume
31,710 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Frankie Muniz to race in ARCA Menards Series
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
James Flynn Joins ARCA biopharma Board of Directors
ABIO ARCA biopharma, Inc.
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
8/04/2021
Today
3/20/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
17
Year Founded
N/A

Profitability

Net Income
$-9,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Michael R. Bristow
    President, Chief Executive Officer & Director
  • Thomas A. Keuer
    Chief Operating Officer
  • C. Jeffrey Dekker
    Chief Financial Officer
  • Christopher David OzeroffChristopher David Ozeroff
    Secretary, Senior Vice President & General Counsel
  • Sharon Perry
    Vice President-Regulatory Affairs & Quality













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 on January 1st, 2023. Since then, ABIO stock has decreased by 9.7% and is now trading at $2.14.
View the best growth stocks for 2023 here
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($2.37) by $2.03.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BML Capital Management LLC (5.96%), Murchinson Ltd. (0.35%), Susquehanna International Group LLP (0.00%), Jane Street Group LLC (0.10%), SG3 Management LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.14.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 3/20/2023 by MarketBeat.com Staff